A Phase I Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety Profile of a Sublingually Administered Cannabidiol /Delta 9-tetrahydrocannabidiol (10: 1) Regimen in Diabetes Type 2 Patients

. 2023 Feb 25;21(1):e132647.

doi: 10.5812/ijpr-132647.

eCollection 2022 Dec.


Item in Clipboard

Shima Afshar et al.

Iran J Pharm Res.



The current study aimed to evaluate the safety profile and efficacy of a cannabis-based sublingual spray, CBDEX10® (containing 100 µg cannabidiol and 10 µg Δ9-tetrahydrocannabinol per puff; CBD/Δ9-THC 10:1), in improving lipid profile and glycemic state of the diabetic patients. Fifty diabetic patients were randomly allocated to the treatment (n = 25; receiving two puffs of CBDEX10® twice daily) or the control groups (n = 25; receiving two puffs of placebo). The primary endpoint of the study was to evaluate the efficacy of the CBDEX10® adjunctive therapy in improving the lipid profile and glycemic state of diabetic patients; the secondary endpoint was to assess the safety profile and tolerability of the spray. A statistically significant decline in total cholesterol [estimated treatment difference (ETD) = -19.73 mg/dL; P < 0.05], triglyceride (ETD = -27.84 mg/dL; P < 0.01), LDL-C (ETD = -5.37 mg/dL; P < 0.01), FBS (ETD = -12 mg/dL; P < 0.01), Hb A1C (ETD = -0.21 mg/dL; P < 0.01) and insulin secretion (ETD = -5.21 mIU/L; P < 0.01) was observable in the patients treated with CBDEX10® at the end of the 8-week treatment period. Regarding safety, the mentioned adjunctive regimen was well, and there were no serious or severe adverse effects. Overall, CBDEX1® sublingual spray could be a new therapeutic agent for lipid and glycemic control in diabetic patients.


Cannabidiol/Delta 9-tetrahydrocannabi; Clinical Trial; Diabetes Melitus; HgA1C.

Conflict of interest statement

Conflict of Interests: Funding or research support: No; Employment: no; Personal financial interests: No; Stocks or shares in companies: No; Consultation fees: No; Patents: No; Personal or professional relations with organizations and individuals (parents and children, wife and husband, family relationships, etc.): No; Unpaid membership in a government or non-governmental organization: No; Are you one of the editorial board members or a reviewer of this journal? Yes.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *